Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451660 | PMC |
| http://dx.doi.org/10.1007/s00259-018-4224-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ONECUT1 activates PSAT1 to facilitate PD-L1 expression and mediate immune evasion of lung squamous cell carcinoma.
Tissue Cell
August 2025
Department of Thoracic Surgery, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530016, China. Electronic address:
Background: PD-1/PD-L1, a classic immune checkpoint commonly employed in targeted therapy, has proven to yield only limited benefits for patients with lung squamous cell carcinoma (LUSC). Unraveling the intrinsic mechanisms underlying the progression of LUSC serves as the foundation for discovering more effective treatment strategies.
Methods: A study was conducted on the differential expression of PSAT1 and ONECUT1 in LUSC based on data from the TCGA database.
68Ga-NODAGA-SNA006 PET/CT Imaging of Tumor CD8+ T-Cell Infiltration Predicts Immunotherapy Response in Lung Cancer.
Clin Nucl Med
September 2025
Department of Pulmonary and Critical Care Medicine, Ruijin Hospital.
Background: This study aimed to evaluate the potential of 68Ga-NODAGA-SNA006 PET/CT imaging as a noninvasive method for assessing immune cell infiltration and predicting treatment response in lung cancer patients undergoing immunotherapy.
Patients And Methods: A prospective study enrolled 8 patients with histologically confirmed lung cancer who received first-line chemotherapy combined with anti-PD-1/PD-L1 immunotherapy. 68Ga-SNA006 PET/CT imaging was performed before treatment.
Screening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.
J Hepatocell Carcinoma
August 2025
Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Background: Conversion therapies after immune checkpoint inhibitors (ICIs) plus tyrosine-kinase inhibitors (TKIs) provide curative surgery chance and prolong survival for unresectable hepatocellular carcinoma (uHCC). However, only some patients have the opportunity to receive conversion therapies. To this end, we aimed to develop and validate a machine-learning model to identify patients who may have the chance to undergo conversion therapy.
View Article and Find Full Text PDFMED12-STAT1-TAP2 axis regulates CD8 + T cell cytotoxicity and mediates immunotherapy outcome in non-small cell lung cancer.
Funct Integr Genomics
September 2025
Department of Thoracic Surgery, Shanghai East Hospital, Tongji University, 1800 Yuntai Road, Shanghai, 200120, China.
Although immunotherapy for late-stage non-small cell lung carcinoma (NSCLC) has been clinically utilized, its prognosis remains highly heterogeneous, prompting us to investigate novel predictive immunotherapy biomarkers for NSCLC. We analyzed the correlations between MED12 nonsynonymous mutations and survival, clinical, genomic, transcriptomic information, and immune infiltration information through data mining across multiple datasets. We also investigated the mechanism of MED12 using luciferase assay, Western blot, ChIP-PCR, and siRNA.
View Article and Find Full Text PDFPD-1, PD-L1, and PD-L2 Expression as Predictive Markers in Rare Feline Mammary Tumors.
Vet Sci
August 2025
CIISA-Center of Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, 1300-477 Lisboa, Portugal.
Feline mammary carcinoma (FMC) exhibits aggressive behavior, with limited treatment options. Given the relevance of the PD-1/PD-L1/PD-L2 axis in human breast cancer immunotherapy, this study assessed PD-1 and its ligands in rare FMC histotypes (n = 48) using immunohistochemistry on tumor cells (TCs), intratumoral lymphocytes (iTILs), and stromal tumor-infiltrating lymphocytes (sTILs). PD-1 was expressed in 13% of TCs, 85% of iTILs, and 94% of sTILs, while PD-L1 was observed in 46% of TCs, 96% of iTILs, and 100% of sTILs.
View Article and Find Full Text PDF